Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 258Breast Neoplasms 218Lung Neoplasms 207Glioblastoma 202Head and Neck Neoplasms 193Prostatic Neoplasms 179Squamous Cell Carcinoma of Head and Neck 171Lymphoma 152Rectal Neoplasms 139Esophageal Neoplasms 125Central Nervous System Neoplasms 122Leukemia 111Brain Neoplasms 107Pancreatic Neoplasms 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Gliosarcoma 87Esophageal Squamous Cell Carcinoma 84Sarcoma 82Uterine Cervical Neoplasms 81Neoplasms 81Lymphoma, Follicular 81Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Non-Hodgkin 75Hodgkin Disease 74Glioma 68Burkitt Lymphoma 67Colorectal Neoplasms 66Leukemia, Lymphocytic, Chronic, B-Cell 63Astrocytoma 63Neoplasm Metastasis 60

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Radiotherapy × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡